#ScienceLink #Madrid2026 #ESMO26 #CheckMate8HW #CCRm
在 CheckMate 8HW（III期）的 SG 最终分析中，nivolumab + ipilimumab 在 CCRm MSI-H/dMMR 患者中，1L 一线治疗相较于 QT 改善了 SG；在所有线别的联合分析中，相较于 nivolumab 也改善了 SG。
⏰ 中位随访时间：68.1 个月
📊 相较于 QT，1L 一线治疗
HR 0.37（IC 95%：0.24–0.57；p<0.0001）
📊 相较于 nivolumab，所有线别
HR 0.61（IC 95%：0.46–0.82；p=0.0009）
⚠️ 相较于 nivolumab，仅限 1L 一线治疗
HR 0.66（IC 95%：0.44–0.99；p=0.0432）
未达到预先设定的 0.0058 显著性阈值。
未出现新的安全性信号，也无新增的治疗相关死亡。
🔗 阅读/收听完整新闻：https://buff.ly/BVtrH9b
21 浏览 · 0 赞 · 0 转发 · 0 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：ScienceLink · x.com